![](/img/cover-not-exists.png)
Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective
Charokopou, M., Vioix, H., Verheggen, B.G., Maddocks, D., Bratt, T., Franks, D.Volume:
17
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2014.08.696
Date:
November, 2014
File:
PDF, 84 KB
english, 2014